Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Menter

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
The British Journal of Dermatology|January 23, 2016
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasisK A Papp, M A Menter, M Raman, et al.
Cutis|November 1, 1988
Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percentR S Medansky, R Bressinck, G W Cole, et al.
The British Journal of Dermatology|April 8, 2021
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-upM Lebwohl, A Deodhar, C E M Griffiths, et al.
The British Journal of Dermatology|July 8, 2015
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trialsK A Papp, M A Menter, M Abe, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 23, 2022
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2A P Fernandez, E Dauden, S Gerdes, et al.
Journal of the American Academy of Dermatology|February 1, 1996
Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994M A Menter, J A See, W J Amend, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
The British Journal of Dermatology|January 23, 2016
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasisK A Papp, M A Menter, M Raman, et al.
Cutis|November 1, 1988
Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percentR S Medansky, R Bressinck, G W Cole, et al.
The British Journal of Dermatology|April 8, 2021
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-upM Lebwohl, A Deodhar, C E M Griffiths, et al.
The British Journal of Dermatology|July 8, 2015
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trialsK A Papp, M A Menter, M Abe, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 23, 2022
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2A P Fernandez, E Dauden, S Gerdes, et al.
Journal of the American Academy of Dermatology|February 1, 1996
Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994M A Menter, J A See, W J Amend, et al.
Pageof 3